Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer-Reference-Cited by-同舟云学术

Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer

Published:2003-04-22 Issue:2 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Wilcken Nicholas¹,Hornbuckle Jo²,Ghersi Davina³

Affiliation:

1. Medical Oncology; Crown Princess Mary Cancer Centre; Westmead Australia

2. Oncology; Western Park Hospital; Sheffield UK

3. Research Policy and Translation; National Health and Medical Research Council; Canberra Australia

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD002747/fullpdf

Reference32 articles.

1. Effects of medroxyprogesterone acetate therapy on advanced or recurrent breast cancer and its influences on blood coagulation and the fibrinolytic system;Abe;Surgery Today,1995

2. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia;Journal of Clinical Oncology,1986

3. A randomized trial of sequential antioestrogen/cytotoxic chemotherapy versus sequential cytotoxic chemotherapy/antioestrogen therapy, versus combined modality therapy, in 339 patients with advanced breast cancer;Forbes;Reviews on Endocrine-related Cancer,1986

4. Management of advanced breast cancer in post-menopausal women. A comparative trial of hormonal therapy, chemotherapy, and a combination of both;Clavel;Semaine des Hopitaux,1982

5. A randomised trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant advanced breast cancer;Dixon;British Journal of Cancer,1992

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Futuro y líneas de investigación clínica del cáncer de mama luminal metastásico;Revisiones en Cáncer;2023

2. Terapia endocrina para el cáncer de MAMA RH+/HER2- avanzado/metastásico en Argentina;Oncología Clínica;2022-10-20

3. Development and validation of nomograms for predicting overall survival and cancer specific survival in locally advanced breast cancer patients: A SEER population-based study;Frontiers in Public Health;2022-09-20

4. ESR1 PvuII polymorphism: from risk factor to prognostic and predictive factor of the success of primary systemic therapy in advanced breast cancer;BMC Cancer;2021-12

5. Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus;Drug Design, Development and Therapy;2021-08